Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 146, Issue 3, 2009, Pages 292-299

  Sutton, Rosemary ^a,e   Venn, Nicola C ^a   Tolisano, Jonathan ^a   Bahar, Anita Y ^a   Giles, Jodie E ^a   Ashton, Lesley J ^a   Teague, Lochie ^b   Rigutto, Gemma ^c   Waters, Keith ^c   Marshall, Glenn M ^a,d   Haber, Michelle ^a   Norris, Murray D ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b STARSHIP CHILDREN S HOSPITAL   (New Zealand)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d SYDNEY CHILDREN'S HOSPITAL   (Australia)

^e CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

Acute lymphoblastic leukaemia; ANZCHOG clinical trial; Minimal residual disease; Real time quantitative PCR; Relapse

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SKULL IRRADIATION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67650478894     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07744.x     Document Type: Article

References (31)

1. Biondi, A., Valsecchi, M.G., Seriu, T., D'Aniello, E., Willemse, M.J., Fasching, K., Pannunzio, A., Gadner, H., Schrappe, M., Kamps, W.A., Bartram, C.R., van Dongen, J.J. Panzer-Grümayer, E.R. (2000) Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia, 14, 1939 1943. (Pubitemid 30821589)
2. Brisco, M.J., Condon, J., Hughes, E., Neoh, S.H., Sykes, P.J., Seshadri, R., Toogood, I., Waters, K., Tauro, G., Ekert, H. Morley, A.A. (1994) Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet, 343, 196 200.
3. Campana, D. (2008) Status of minimal residual disease testing in childhood haematological malignancies. British Journal of Haematology, 143, 481 489. Review.
4. Cave, H., van der Werff ten Bosch, J., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B. Vilmer, E. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. New England Journal of Medicine, 339, 591 598.
5. Choi, S., Henderson, M.J., Kwan, E., Beesley, A.H., Sutton, R., Bahar, A.Y., Giles, J., Venn, N.C., Pozza, L.D., Baker, D.L., Marshall, G.M., Kees, U.R., Haber, M. Norris, M.D. (2007) Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood, 110, 632 639.
6. Coustan-Smith, E., Behm, F.G., Sanchez, J., Boyett, J.M., Hancock, M.L., Raimondi, S.C., Rubnitz, J.E., Rivera, G.K., Sandlund, J.T., Pui, C.H. Campana, D. (1998) Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet, 351, 550 554. (Pubitemid 28077560)
7. Coustan-Smith, E., Sancho, J., Hancock, M.L., Boyett, J.M., Behm, F.G., Raimondi, S.C., Sandlund, J.T., Rivera, G.K., Rubnitz, J.E., Ribeiro, R.C., Pui, C.H. Campana, D. (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 96, 2691 2696. (Pubitemid 30770361)
8. Coustan-Smith, E., Sancho, J., Behm, F.G., Hancock, M.L., Razzouk, B.I., Ribeiro, R.C., Rivera, G.K., Rubnitz, J.E., Sandlund, J.T., Pui, C.H. Campana, D. (2002) Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood, 100, 52 58. (Pubitemid 35177428)
9. van Dongen, J.J.M., Seriu, T., Panzer-Grümayer, E.R., Biondi, A., Pongers-Willemse, M.J., Corral, L., Stolz, F., Schrappe, M., Masera, G., Kamps, W.A., Gadner, H., van Wering, E.R., Ludwig, W.D., Basso, G., de Bruijn, M.A., Cazzaniga, G., Hettinger, K., van der Does-van den Berg, A., Hop, W.C., Riehm, H. Bartram, C.R. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet, 352, 1731 1738. (Pubitemid 28534955)
10. van Dongen, J.J., Langerak, A.W., Brüggemann, M., Evans, P.A., Hummel, M., Lavender, F.L., Delabesse, E., Davi, F., Schuuring, E., García-Sanz, R., van Krieken, J.H., Droese, J., González, D., Bastard, C., White, H.E., Spaargaren, M., González, M., Parreira, A., Smith, J.L., Morgan, G.J., Kneba, M. Macintyre, E.A. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 17, 2257 2317. (Pubitemid 38072572)
11. Dworzak, M.N., Froschl, G., Printz, D., Mann, G., Potschger, U., Muhlegger, N., Fritsch, G. Gadner, H. (2002) Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood, 99, 1952 1958. (Pubitemid 34525474)
12. Esteve, J., Escoda, L., Martín, G., Rubio, V., Díaz-Mediavilla, J., González, M., Rivas, C., Alvarez, C., González San Migue, l.J.D., Brunet, S., Tomás, J.F., Tormo, M., Sayas, M.J., Sánchez Godoy, P., Colomer, D., Bolufer, P. Sanz, M.A. (2007) Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia, 21, 446 452. (Pubitemid 46306555)
13. Flohr, T., Schrauder, A., Cazzaniga, G., Panzer-Grümayer, R., van der Velden, V., Fischer, S., Stanulla, M., Basso, G., Niggli, F.K., Schäfer, B.W., Sutton, R., Koehler, R., Zimmermann, M., Valsecchi, M.G., Gadner, H., Masera, G., Schrappe, M., van Dongen, J.J., Biondi, A. Bartram, C.R. (2008) Minimal residual disease (MRD)-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia (ALL). Leukemia, 22, 771 782. (Pubitemid 351552626)
14. Fronkova, E., Mejstrikova, E., Avigad, S., Chik, K.W., Castillo, L., Manor, S., Reznickova, L., Valova, T., Zdrahalova, K., Hrusak, O., Jabali, Y., Schrappe, M., Conter, V., Izraeli, S., Li, C.K., Stark, B., Stary, J. Trka, J. (2008) Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia, 22, 989 997. (Pubitemid 351689881)
15. Gaynon, P.S., Desai, A.A., Bostrom, B.C., Hutchinson, R.J., Lange, B.J., Nachman, J.B., Reaman, G.H., Sather, H.N., Steinherz, P.G., Trigg, M.E., Tubergen, D.G. Uckun, F.M. (1997) Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer, 80, 1717 1726. (Pubitemid 27475928)
16. Kwan, E., Norris, M.D., Zhu, L., Ferrara, D., Marshall, G.M. Haber, M. (2000) Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction. British Journal of Haematology, 109, 430 434. (Pubitemid 30350730)
17. Lo Coco, F., Diverio, D., Avvisati, G., Petti, M.C., Meloni, G., Pogliani, E.M., Biondi, A., Rossi, G., Carlo-Stella, C., Selleri, C., Martino, B., Specchia, G. Mandelli, F. (1999) Therapy of molecular relapse in acute promyelocytic leukemia. Blood, 94, 2225 2229. (Pubitemid 29467668)
18. Marshall, G.M., Haber, M., Kwan, E., Zhu, L., Ferrara, D., Xue, C., Brisco, M.J., Sykes, P.J., Morley, A., Webster, B., Dalla Pozza, L., Waters, K. Norris, M.D. (2003) Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. Journal of Clinical Oncology, 21, 704 709. (Pubitemid 46621906)
19. Mortuza, F.Y., Papaioannou, M., Moreira, I.M., Coyle, L.A., Gameiro, P., Gandini, D., Prentice, H.G., Goldstone, A., Hoffbrand, A.V. Foroni, L. (2002) Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. Journal of Clinical Oncology, 20, 1094 1104. (Pubitemid 34141855)
20. Nyvold, C., Madsen, H.O., Ryder, L.P., Seyfarth, J., Svejgaard, A., Clausen, N., Wesenberg, F., Jonsson, O.G., Forestier, E. Schmiegelow, K. (2002) Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood, 99, 1253 1258. (Pubitemid 34547078)
21. Panzer-Grümayer, E.R., Schneider, M., Panzer, S., Fasching, K. Gadner, H. (2000) Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood, 95, 790 794. (Pubitemid 30062697)
22. Pongers-Willemse, M.J., Seriu, T., Stolz, F., d'Aniello, E., Gameiro, P., Pisa, P., Gonzalez, M., Bartram, C.R., Panzer-Grümayer, E.R., Biondi, A., San Miguel, J.F. van Dongen, J.J. (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia, 13, 110 118. (Pubitemid 29043725)
23. Raff, T., Gökbuget, N., Lüschen, S., Reutzel, R., Ritgen, M., Irmer, S., Böttcher, S., Horst, H.A., Kneba, M., Hoelzer, D. Brüggemann, M. (2007) Molecular relapse in adult standard risk ALL patients detected by prospective MRD-monitoring during and after maintenance treatment - data from the GMALL 06/99 and 07/03 trials. Blood, 109, 910 915. (Pubitemid 46220634)
24. Ryan, J., Quinn, F., Meunier, A., Boublikova, L., Crampe, M., Tewari, P., O'Marcaigh, A., Stallings, R., Neat, M., O'Meara, A., Breatnach, F., McCann, S., Browne, P., Smith, O. Lawler, M. (2009) Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. British Journal of Haematology, 144, 107 115.
25. Sutton, R., Bahar, A.Y., Kwan, E., Giles, J.E., Venn, N.C., Tran, S., Hackenberg, N., Pozza, L.D., Marshall, G.M., Haber, M., van der Velden, V.H. Norris, M.D. (2008) Improving minimal residual disease testing in precursor-B-ALL based on immunoglobulin kappa and heavy chain gene rearrangements. Leukemia, 22, 2265 2267.
26. Szczepanski, T., van der Velden, V.H., Hoogeveen, P.G., de Bie, M., Jacobs, D.C., van Wering, E.R. van Dongen, J.J. (2004) Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. Blood, 103, 3798 3804. (Pubitemid 38596298)
27. van der Velden, V.H.J., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J. van Dongen, J.J.M. (2003) Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia, 17, 1013 1034. (Pubitemid 36722231)
28. van der Velden, V.H.J., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer-Grümayer, R., Flohr, T., Sutton, R., Cave, H., Madsen, H.O., Cayuela, J.M., Trka, J., Eckert, C., Foroni, L., Zur Stadt, U., Beldjord, K., Raff, T., van der Schoot, C.E. van Dongen, J.J. (2007) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative data. Leukemia, 21, 706 713.
29. van der Velden, V.H., Wijkhuijs, J.M. van Dongen, J.J. (2008) Non-specific amplification of patient-specific Ig/TCR gene rearrangements depends on the time point during therapy: implications for minimal residual disease monitoring. Leukemia, 22, 641 644.
30. Zhou, J., Goldwasser, M.A., Li, A., Dahlberg, S.E., Neuberg, D., Wang, H., Dalton, V., McBride, K.D., Sallan, S.E., Silverman, L.B. Gribben, J.G. Dana-Farber Cancer Institute ALL Consortium (2007) Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood, 110 : 1607 1611. (Pubitemid 47443978)
31. Ziegler, D.S., Dalla Pozza, L., Waters, K.D. Marshall, G.M. (2005) Advances in childhood leukaemia: successful clinical-trials research leads to individualised therapy. Medical Journal of Australia, 182, 78 81.